¿Existe respuesta diferente a los distintos inhibidores de PCSK9?
| Autor: | O. Caamaño Selma, Á. Asenjo Mota, R. Sánchez-Aquino González |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry PCSK9 fungi Subtilisin 030204 cardiovascular system & hematology Proprotein convertase 03 medical and health sciences 0302 clinical medicine Internal medicine Internal Medicine Kexin Medicine In patient 030212 general & internal medicine Cardiology and Cardiovascular Medicine business |
| Zdroj: | Hipertensión y Riesgo Vascular. 37:42-44 |
| ISSN: | 1889-1837 |
| DOI: | 10.1016/j.hipert.2019.04.001 |
| Popis: | The case is presented of a 62-year-old patient who required lipid-lowering therapy with proprotein convertase subtilisin/kexin type9 (PCSK9). It was empirically decided to change one drug to another of the two currently available, obtaining a different response. Our objective is to present our experience and to consider a possible therapeutic option in patients in whom, exceptionally, this could happen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect